CURIS INC (CRIS)
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Address
128 SPRING STREET
LEXINGTON, MA 02421
Founded
2000
Number of Employees
49
Website
http://www.curis.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)